Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The new centre will comprise a team of 50 highly experienced specialists
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Subscribe To Our Newsletter & Stay Updated
